Ultra-Long-Acting Injectable GLP-1 RA Shows Promise for Supporting Weight Management in Individuals With and Without Type 2 Diabetes
New research supports monthly dosing as a next‑generation opportunity to improve weight loss NEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential benefits of using berobenatide, an investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) across...
New research supports monthly dosing as a next‑generation opportunity to improve weight loss NEW ORLEANS, June 6, 2026 /PRNewswire/ -- New data highlight the potential benefits of using berobenatide, an investigational injectable glucagon-like peptide-1 receptor agonist (GLP-1 RA) across...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.